

REMARKS

Upon entry of this amendment, claims 62-66, 68-70, 73-78, 81-88, 91-98, 99, 135, 136, and 139-150 will be pending in the application. Claims 64, 75, 83, and 93 are amended to independent form and should be allowable. (Office Action, page 6.) Claim 62 is amended to recite the step recited in claim 67. Claim 73 is amended to incorporate the limitation of claim 77. Claim 77 is amended to depend from claim 75. Claim 81 is amended to recite the step recited in claim 88. Claim 88 is amended to depend from claim 83. Claim 91 is amended to recite the step recited in claim 97. Claim 97 is amended to depend from claim 93. Claims 139-150 are added. Exemplary support for the new claims is located in paragraph [0072] and original claims 8, 85, 88, 96, and 97. Claims 1-61, 67, 71, 72, 77, 79, 80, 88-90, 97, 100-134, 137, and 138 are canceled. No new matter is introduced.

The obviousness rejection should be withdrawn.

Claims 62, 63, 66, 69, 70, 73, 74, 78, 81, 82, 85-87, 91, 92, 95, 96, 99, 135, and 136 are rejected under 35 U.S.C. § 103 for alleged obviousness over U.S. Pat. No. 6,808,894 to Nicolaides *et al.* in view of Borrebaeck *et al.*, *Adv. Drug Del. Rev.*, 1988, 2:143-165. Without conceding the propriety of the rejection and in an effort to advance prosecution of the application, claim 62 has been amended to recite the step recited in claim 67; claim 73 has been amended to recite the step recited in claim 77; claim 81 has been amended to recite the step recited in claim 88; and claim 91 has been amended to recite the step recited in claim 97. Withdrawal of the rejection is respectfully requested.

The obviousness-type double patenting rejection should be withdrawn.

Claims 62, 63, 66, 69, 70, 73, 74, 78, 81, 82, 85-87, 91, 92, 95, 96, 99, 135, and 136 are rejected for alleged obviousness-type double patenting over claims 1-21 of U.S. Pat. No. 6,808,894 to Nicolaides *et al.* in view of Borrebaeck *et al.*, *Adv. Drug Del. Rev.*, 1988, 2:143-165 and Yelton *et al.*, *J. Immunol.*, 1995, 155:1994-2004. Without conceding the propriety of the rejection and in an effort to advance prosecution of the application, claim 62 has been amended to recite the step recited in claim 67; claim 73 has been amended to recite the step recited in claim 77; claim 81 has been amended to recite the step recited in claim 88; and

DOCKET NO.: MOR-0251
Application No.: 10/714,228
Office Action Dated: October 21, 2008

PATENT

claim 91 has been amended to recite the step recited in claim 97. Withdrawal of the rejection is respectfully requested.

Conclusion

Applicants believe that the foregoing constitutes a complete and full response to the official action of record. An early and favorable action is accordingly respectfully requested. Should any issues remain upon entry of the present amendment, the undersigned may be contacted at 215.564.8978.

Respectfully submitted,

Date: December 24, 2008

/ Felicity E. Groth /
Felicity E. Groth
Registration No. 47,042

Woodcock Washburn LLP
Cira Centre
2929 Arch Street, 12th Floor
Philadelphia, PA 19104-2891
Telephone: (215) 568-3100
Facsimile: (215) 568-3439